ScienceDaily (Mar. 2, 2009) — A new report describes the development of a cell-permeable inhibitor that specifically blocks the contribution of the protein RANK to the formation and function of the cells responsible for breaking down bone.

Importantly, this drug protected against bone loss in two mouse models of diseases associated with bone destruction, leading to the suggestion that this approach might be beneficial to individuals with diseases such as osteoporosis.

Soo Young Lee and colleagues, at Ewha Womans University, Republic of Korea, have developed a cell-permeable inhibitor of the mouse protein RANK (which they termed RRI) that is likely to aid in the development of selective drugs to treat diseases that involve substantial bone loss, for example, osteoporosis, periodontitis, and arthritis.

Central to understanding diseases that involve substantial loss of bone density, and thereby loss of bone strength, is insight into the molecules that regulate the formation and function of the cells that slowly breakdown bone, cells known as osteoclasts.

One molecule known to regulate both these processes is RANK, however, its utility as a target for drugs that prevent bone destruction might to be limited, as it is involved in many other biological functions.

The authors designed RRI to target a region of RANK that they recently found to be specific for the formation of osteoclasts. RRI was found to inhibit in vitro RANKL-induced formation of mouse osteoclasts and in vitro osteoclast-mediated bone destruction. More importantly, it protected against bone loss in two mouse models of diseases associated with bone destruction, leading to the suggestion similar drugs might be beneficial to individuals with diseases that involve bone destruction, such as osteoporosis.

Story Source:

Adapted from materials provided by Journal of Clinical Investigation, via EurekAlert!, a service of AAAS.

Journal Reference:

1. Kim et al. Selective inhibition of RANK blocks osteoclast maturation and function and prevents bone loss in mice. Journal of Clinical Investigation, 2009; DOI: 10.1172/JCI36809

Related Stories

Insights Into Osteosarcoma In Cats And Dogs May Improve Palliative Care (Mar. 6, 2007) — Researchers at the University of Illinois have found that a molecular pathway known to have a role in the progression of bone cancer in humans is also critical to the pathology of skeletal tumors in ...  > read more

Vitamin D Signals To Prevent Bone Loss During Osteoporosis (Jan. 24, 2006) — Researchers at the National Center for Geriatrics and Gerontology, Japan, show that vitamin D prevents bone loss in mice by suppressing the protein c-Fos, thereby inhibiting development of ...  > read more

Targeting A Single Gene Could Inhibit Bone Decay And Stimulate Bone Growth (Dec. 9, 2006) — Researchers at the University of Pennsylvania's School of Medicine have found by targeting the function of a single gene that it is possible to inhibit bone decay while simultaneously stimulating ...  > read more

New Cause of Osteoporosis: Mutation in a miroRNA (Nov. 20, 2009) — Many biological processes are controlled by small molecules known as microRNAs. Researchers have now identified a previously unknown microRNA (miR-2861) as crucial to bone maintenance in mice and ...  > read more

Search ScienceDaily

Baking Out DNA